Compare MORN & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MORN | STVN |
|---|---|---|
| Founded | 1984 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Investment Managers | Containers/Packaging |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 7.4B |
| IPO Year | 2005 | 2021 |
| Metric | MORN | STVN |
|---|---|---|
| Price | $216.21 | $23.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $333.33 | $25.88 |
| AVG Volume (30 Days) | ★ 359.2K | 354.5K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.85% | 0.27% |
| EPS Growth | 16.18 | ★ 19.61 |
| EPS | ★ 8.80 | 0.60 |
| Revenue | ★ $2,395,400,000.00 | $1,373,219,524.00 |
| Revenue This Year | $8.52 | $8.33 |
| Revenue Next Year | $7.45 | $10.12 |
| P/E Ratio | ★ $24.47 | $38.75 |
| Revenue Growth | ★ 7.76 | 6.97 |
| 52 Week Low | $202.89 | $17.81 |
| 52 Week High | $365.00 | $28.00 |
| Indicator | MORN | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 48.12 |
| Support Level | $205.97 | $22.71 |
| Resistance Level | $215.23 | $24.01 |
| Average True Range (ATR) | 4.04 | 1.24 |
| MACD | 1.07 | 0.12 |
| Stochastic Oscillator | 76.89 | 53.77 |
Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.